“NoNews”

🇩🇰

Novo Nordisk

Turbulence for the Danish pharma giant

Update

09.03.26

Statusopdateringen for Novo Nordisk her i marts 2026 er præget af et markant skift. Efter et meget turbulent årsmøde og regnskabsaflæggelse i februar, hvor aktien oplevede store fald, forsøger selskabet nu at stabilisere kursen gennem strategiske partnerskaber og produktionsudvidelser.

1. Det strategiske partnerskab (Seneste nyt: 9. marts 2026)

Novo Nordisk har netop indgået et opsigtsvækkende partnerskab med det amerikanske telehealth-selskab Hims & Hers.

• Forlig: Novo har droppet deres søgsmål mod Hims & Hers vedrørende kopiprodukter.

• Samarbejde: Hims & Hers skal fremover sælge Novo Nordisks officielle, FDA-godkendte vægttabsmedicin (GLP-1) direkte på deres platform. Dette ses som et træk for at sikre markedsandele og bekæmpe uautoriserede kopier.

2. Finansiel status og "Blodbadet" i februar

2026 er blevet kaldt et "transitionsår" for Novo, og det har været hårdt for aktiekursen:

• Skuffende guidance: Ved årsregnskabet i februar meldte Novo ud, at de forventer et fald i både salg og driftsindtjening (EBIT) på 5-13 % i 2026. Det var markant værre end analytikernes forventninger.

• Aktiekurs: Kursen ligger aktuelt omkring 247-248 DKK (pr. 9. marts). Selvom nogle analytikere ser en stor "upside" på sigt (op mod 34 %), befinder aktien sig i en teknisk nedtrend efter at have tabt over 20 % på kort tid.

• Aktietilbagekøb: For at støtte kursen har Novo iværksat et tilbagekøbsprogram på 15 milliarder kr. for 2026.

3. Pipeline og Produktion

• "Wegovy på pille": Den orale version af semaglutid er nu lanceret i USA og er en af de vigtigste vækstmotorer for at modvirke prispres på de injektbare versioner.

• Udvidelse i Irland: Den 2. marts annoncerede Novo en investering på over 400 millioner euro i deres faciliteter i Athlone, Irland, specifikt for at øge kapaciteten af tablet-produktion.

• CagriSema-skuffelse: En af årsagerne til den negative stemning var skuffende data fra REDEFINE 4-studiet i slutningen af februar, hvor det primære endemål ikke blev nået helt som håbet.

🇺🇸 🇬🇧

Novo Nordisk Status Update – March 2026

The status of Novo Nordisk as of March 2026 is defined by a significant strategic shift. Following a turbulent annual meeting and earnings report in February—which triggered sharp declines in the stock price—the company is now attempting to stabilize through strategic partnerships and production expansions.

1. Strategic Partnership (Latest: March 9, 2026)

Novo Nordisk has just entered a high-profile partnership with the American telehealth company Hims & Hers.

• Settlement: Novo has dropped its lawsuit against Hims & Hers regarding compounded (copycat) products.

• Collaboration: Moving forward, Hims & Hers will sell Novo Nordisk's official, FDA-approved weight-loss medication (GLP-1) directly on their platform. This is seen as a move to secure market share and combat unauthorized versions.

2. Financial Status and the "February Bloodbath"

2026 has been labeled a "transition year" for Novo, and it has been tough on the share price:

• Disappointing Guidance: During the February earnings call, Novo announced that they expect a decline in both sales and operating profit (EBIT) of 5–13% in 2026. This was significantly worse than analyst expectations.

• Stock Price: The price is currently hovering around DKK 247–248 (as of March 9). While some analysts see a major long-term "upside" (up to 34%), the stock is in a technical downtrend after losing over 20% in a short period.

• Share Buyback: To support the price, Novo has launched a DKK 15 billion share buyback program for 2026.

3. Pipeline and Production

• "Wegovy in a Pill": The oral version of semaglutide has now launched in the U.S. and is one of the key growth drivers to counteract price pressure on injectable versions.

• Expansion in Ireland: On March 2, Novo announced an investment of over €400 million in its facilities in Athlone, Ireland, specifically to increase tablet production capacity.

• CagriSema Disappointment: Part of the negative sentiment stemmed from disappointing data from the REDEFINE 4 study in late February, where the primary endpoint was not met as convincingly as hoped.